Tapentadol (CG5503)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1030 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the knee, in comparison with placebo and Oxycodone Controlled Release (CR).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

NCT00486811

Pain Knee Osteoarthritis

COMPLETED PHASE3

Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis

NCT00745069

Osteoarthitis Chronic Pain Knee Pain

COMPLETED PHASE2

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

NCT00449176

Low Back Pain

COMPLETED PHASE3

A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery

NCT00361582

Osteoarthritis Pain Assessment Arthralgia

COMPLETED PHASE3

A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

NCT00364546

Osteoarthritis Pain Intensity Assessment Arthralgia +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this randomized (study medication assigned to patients by chance), double-blind (neither patient nor investigator knows the study medication) , phase III, placebo and active controlled trial is to evaluate the efficacy and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain from osteoarthritis (OA) of the knee. The study is being conducted for registration and approval of tapentadol (CG5503) in the US and outside the US. The trial will consist of five periods: screening (to assess eligibility) , washout (3-7 days with determination of a baseline pain intensity), titration (of dose over 3 weeks to the optimal individual level) , maintenance (investigational drug intake for 12 weeks with adjustments allowed), and follow-up (2 weeks post treatment discontinuation). The study hypothesis is that the study drug will be more effective than placebo in reducing patients pain intensity. The Secondary objectives include the collection of pharmacokinetic (related to how the body uses the drug) information for dose verification. The trial objectives will be assessed by comparing the baseline pain level to the level of week 12 of the maintenance phase. This will be done by looking at the patient's pain diary information. Titrate tapentadol (CG5503) ER (extended release) 50mg to patient's optimal dose ranging between 100mg and 250mg twice a day; Oxycodone CR (controlled release) 10mg to 50mg twice a day; Placebo (no active ingredients). All doses of trial treatment will be taken orally with approximately 120 mL of water with or without food for a maximum timeframe of 15 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

001

tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks

Group Type EXPERIMENTAL

tapentadol (CG5503)

Intervention Type DRUG

50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks

002

oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks

Group Type ACTIVE_COMPARATOR

oxycodone

Intervention Type DRUG

10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks

003

placebo matching placebo twice a day (BID) during 15 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

matching placebo twice a day (BID) during 15 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oxycodone

10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks

Intervention Type DRUG

placebo

matching placebo twice a day (BID) during 15 weeks

Intervention Type DRUG

tapentadol (CG5503)

50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with osteoarthritis of the knee based on the American College of Rheumatology (ACR) criteria and functional capacity class of I-III
* patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy
* Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to \<160 mg of oral morphine
* baseline score of greater than or equal to 5 on an 11-point numerical rating scale, calculated as the average pain intensity during the last 3 days prior to randomization.

Exclusion Criteria

* History of alcohol and/or drug abuse in Investigator's judgement
* history of significant liver insufficiency
* chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months
* life-long history of seizure disorder or epilepsy
* history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated
* uncontrolled hypertension
* patients with severely impaired renal function
* patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No